Senior Medical Advisor

Senior Medical Advisor – Madrigal Pharmaceuticals (Munich, Bavaria, Germany)

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction‑associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation, and premature mortality. Every member of our team shares the purpose of leading the fight against MASH.

Our medication, Rezdiffra (resmetirom), is a once‑daily oral liver‑directed THR‑β agonist designed to target key underlying causes of MASH. It is the first and only medication approved by both the FDA and European Commission for the treatment of moderate to advanced fibrosis (F2–F3). A Phase 3 outcomes trial is evaluating Rezdiffra for compensated MASH cirrhosis (F4c).

Madrigal builds a dynamic, inclusive, and high‑performing culture that values scientific excellence, operational rigor, and collaboration. We strengthen our workforce strategy to ensure the right talent at the right time in the right way.

The Medical Advisor will plan and lead pre‑launch and launch activities in the therapeutic field of metabolic dysfunction‑associated steatohepatitis (MASLD/MASH). The Advisor is the medical specialist in the field and an expert in the medical affairs landscape within the territory. A strong understanding of the healthcare system, diagnostic pathways, and stakeholder landscape is essential. The role represents Madrigal externally through scientific discussions with thought leaders, clinical trial investigators, and other healthcare professionals.

• Demonstrate support for clinical trials and engage with external experts on the generation of scientific data.
• Collaborate with clinical organizations to enhance patient enrollment in company‑sponsored clinical trials by identifying appropriate trial sites and interacting with investigators in ongoing trials.
• Deeply understand the fatty liver therapeutic area (MASLD/MASH), key stakeholders, and the healthcare landscape (including reimbursement, access, and diagnostic testing) in the territory.
• Help execute country medical plans locally by providing medical expertise in MASLD/MASH and engaging with the medical community in hepatology, gastroenterology, and endocrinology.
• Attend relevant scientific meetings and conferences and support the development of summaries of key data presentations or symposiums.
• Identify, develop, and maintain relationships with leading influential experts, key thought leaders (TLs), and health‑care professionals (HCPs) in fields of medicine or research relevant to MASLD/MASH; build peer‑to‑peer relationships with TLs and HCPs.
• Engage key TLs, HCPs, and investigators in proactive scientific exchange on disease landscape, and reactive exchange on mode of action and clinical data.
• Represent the company at selected scientific congresses and professional society meetings.
• Collaborate with other internal team members (e.g., commercial, payer/access/HTA, regulatory, clinical development) to share regional insights/learnings and contribute to respective strategies.
• Serve as a key member of the medical strategy team to share regional actionable insights and develop the medical strategy.
• Respond to external inquiries and deliver appropriate clinical and scientific information.
• Develop and deliver scientific trainings.
• Gather detailed information from TLs/HCPs and report back to help develop clinical as well as commercial strategy.
• Operate in a highly ethical manner and comply with all laws, regulations, and policies.
• Complete mandatory training in assigned timelines upon hire and when new policies, SOPs, or guidance are issued.
• Adhere to internal standard processes and comply with regulatory and compliance requirements.

• 7‑10 years of experience as a Medical Advisor, MSL, or related field in the pharmaceutical/biotechnology industry.
• Life Sciences Master’s (MSc), Diploma, or Doctorate degree.
• Hepatology / Gastroenterology and/or Fatty Liver experience strongly preferred.
• Working knowledge of the local regulatory, health‑technology assessment, and disease‑management landscape for NAFLD/NASH…